Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT05796726
- Locations
- 🇩🇪
Novartis Investigative Site, Würzburg, Germany
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05791097
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
- Conditions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT05787236
- Locations
- 🇮🇩
Mangga Besar Clinic, Jakarta, Indonesia
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05776888
- Locations
- 🇦🇹
Novartis Investigative Site, Vienna, Austria
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 304
- Registration Number
- NCT05776927
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 381
- Registration Number
- NCT05767034
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Paramount Med Rsrch and Consult LLC, Middleburg Heights, Ohio, United States
🇬🇧Novartis Investigative Site, Wolverhampton, United Kingdom
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT05763875
- Locations
- 🇺🇸
Southern Clin Research Clinic ., Zachary, Louisiana, United States
🇲🇽Novartis Investigative Site, Queretaro, Mexico
🇺🇸Hillcrest Medical Research, DeLand, Florida, United States
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT05764265
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom
🇺🇸Pulmonary Associates PA ., Mesa, Arizona, United States
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05758415
- Locations
- 🇺🇸
Medvin Clinical Research, Van Nuys, California, United States
🇺🇸Horizon Clinical Research, La Mesa, California, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT05758402
- Locations
- 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of